This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Hvidovre Hospital. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Long Van Pham: Innovator in Hepatitis C Research
Introduction
Long Van Pham is a notable inventor based in Hvidovre, Denmark. He has made significant contributions to the field of virology, particularly in the study of hepatitis C virus (HCV). His work focuses on developing innovative solutions that aid in the understanding and treatment of this virus.
Latest Patents
Long Van Pham holds a patent for an "Efficient cell culture system for hepatitis C virus genotype 6A." This invention relates to nucleic acid sequences that encode hepatitis C viruses of genotype 6a. These sequences are essential for fundamental research on HCV and play a crucial role in the search for antivirals and vaccines against the virus. The patent highlights the capability of these nucleic acid sequences to express the virus when transfected into cells, demonstrating their potential for replication and infectivity in cultured cells. He has 1 patent to his name.
Career Highlights
Long Van Pham is affiliated with Hvidovre Hospital, where he conducts his research. His work has been instrumental in advancing the understanding of hepatitis C and developing potential therapeutic strategies. His dedication to research has positioned him as a key figure in the field.
Collaborations
Long Van Pham has collaborated with esteemed colleagues, including Jens Bukh and Santseharay Ramirez Almelda. These partnerships have enhanced the scope and impact of his research efforts.
Conclusion
Long Van Pham's contributions to hepatitis C research through his innovative patent and collaborations underscore his importance in the field of virology. His work continues to pave the way for advancements in the understanding and treatment of this significant health issue.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
